Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MMP1 | P03956 | 2/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.58 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.56 |
| ▸ | NDUFS8 | O00217 | 1/20 | 0.55 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.55 |
| ▸ | NDUFAB1 | O14561 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449626 | 1.00 | LMNA (0.66) | LMNAKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL4657743 | 0.90 | S1PR1 (0.69) | LMNAKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL4657740 | 0.90 | S1PR1 (0.69) | LMNAKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL4657194 | 0.87 | LMNA (0.61) | LMNAKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL4657195 | 0.87 | LMNA (0.61) | LMNAKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL451121 | 0.82 | S1PR1 (0.61) | LMNAKMT2AALDH1A1MEN1S1PR1 | |
| SCHEMBL451122 | 0.82 | S1PR1 (0.61) | LMNAKMT2AALDH1A1MEN1S1PR1 | |
| SCHEMBL8380557 | 0.81 | SMN1; SMN2 (0.62) | LMNAKMT2AALDH1A1MEN1SMN1; SMN2 | |
| SCHEMBL17117366 | 0.80 | MMP1 (0.80) | LMNAKMT2AALDH1A1MEN1MMP1 | |
| SCHEMBL7377120 | 0.80 | MMP1 (0.80) | LMNAKMT2AALDH1A1MEN1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | claimed |
| EP-1219605-B1 | UREA COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-10 | — | — | EP | claimed |
| EP-1336407-B1 | COMPOSITION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC AND ITS USE FOR THE TREATMENT OF HYPERTENSION | SANKYO CO (JP) | 2006-05-03 | — | — | EP | claimed |
| EP-1595540-A1 | Composition containing an angiotensin II receptor antagonist and a diuretic and its use for the treatment of hypertension | Sankyo Company Limited (JP) | 2005-11-16 | — | — | EP | claimed |
| US-20050113367-A1 | Pharmaceutical composition | SANKYO COMPANY, LIMITED (JP) | 2005-05-26 | — | — | US | claimed |
| US-6878703-B2 | Pharmaceutical composition | SANKYO COMPANY, LIMITED (JP) | 2005-04-12 | — | — | US | claimed |
| US-20040002529-A1 | Pharmaceutical composition | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | claimed |
| EP-1336407-A1 | MEDICINAL COMPOSITIONS | Sankyo Company, Limited (JP) | 2003-08-20 | — | — | EP | claimed |
| EP-1087977-B1 | THIENODIPYRIDINE DERIVATIVES, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-0723965-B1 | NOVEL CEPHALOSPORIN DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2001-05-30 | — | — | EP | claimed |
| US-5827845-A | BACTERICIDES | MEIJI SEIKA KAISHA, LTD. (JP) | 1998-10-27 | — | — | US | claimed |
| EP-0723965-A1 | NOVEL CEPHALOSPORIN DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 1996-07-31 | — | — | EP | claimed |
| EP-0186586-B1 | CEPHEM COMPOUNDS AND THE PRODUCTION THEREOF | MEIJI SEIKA KAISHA LTD. (JP) | 1990-09-26 | — | — | EP | claimed |
| EP-0355821-A2 | A process for preparing cephem prodrug esters | Bristol-Myers Squibb Company (US) | 1990-02-28 | — | — | EP | claimed |
| US-4687769-A | ANTIBIOTICS | MEIJI SEIKA KAISHA, LTD. (JP) | 1987-08-18 | — | — | US | claimed |
| US-4613595-A | PENCILLIN ANTIBIOTICS | SANKYO COMPANY LIMITED (JP) | 1986-09-23 | — | — | US | claimed |
| EP-0186586-A2 | Cephem compounds and the production thereof | MEIJI SEIKA KAISHA LTD. (JP) | 1986-07-02 | — | — | EP | claimed |
| JP-63041475-A | — | — | None | — | — | JP | disclosed |
| EP-0039477-A1 | Use of 1,3-Dioxolen-2-one derivatives | KANEBO, LTD. (JP) | 1981-11-11 | — | — | EP | disclosed |
| EP-0039086-A2 | Novel ampicillin esters and production thereof | KANEBO, LTD. (JP) | 1981-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113367-A1 | Pharmaceutical composition | AGTR2, AGTR1, REN | LMNA 3440/4885KMT2A 3920/4885ALDH1A1 559/4885 |
| US-20040002529-A1 | Pharmaceutical composition | AGTR2, AGTR1, REN | LMNA 2646/4885KMT2A 3457/4885ALDH1A1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.